Elena Zamagni
0000-0003-1422-7305
161 papers found
Refreshing results…
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
18F-FDG PET/CT FOCAL, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma
The Role of Positron Emission Tomography with 18F-Fluorodeoxyglucose Integrated with Computed Tomography in the Evaluation of Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation
Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: Clinical and molecular analyses of a phase 3 study
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma
Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death
Positron Emission Tomography With Computed Tomography–Based Diagnosis of Massive Extramedullary Progression in a Patient With High-Risk Multiple Myeloma
The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations
Missing publications? Search for publications with a matching author name.